Premium
Use of gallium‐67 scanning in the management of lymphoma
Author(s) -
Bakshi S.,
Bender M. A.
Publication year - 1973
Publication title -
journal of surgical oncology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.201
H-Index - 111
eISSN - 1096-9098
pISSN - 0022-4790
DOI - 10.1002/jso.2930050604
Subject(s) - medicine , lymphoma , nuclear medicine , radiation therapy , radiology , chemotherapy , malignant lymphoma , pathology
There has been considerable interest recently in the possibility that gallium‐67 citrate may be of clinical value as a tumor seeking scanning agent. Since its discovery by Edwards and Hayes (1969), a number of reports have been published recording uptake in a variety of tumors, both primary and metastatic (Higasi et al., 1970; Winchell et al., 1970). The observation of Hayes et al. (1970), based on autoradiographs of experimental tumors, that the radioisotope is taken up in the cytoplasm in malignant cells and that uptake is greater in viable than in necrotic tumor has stimulated its use in following patients with lymphoma to assess the efficacy of the therapy administeted. At our Institution an assessment has been made of the potential value of 67 Ga citrate scanning in the management of lymphoma. Interesting scans showing the usefulness and difficulties with this agent are presented. A total of 79 scans were reviewed. The majority of the patients studied has received either chemotherapy or radiotherapy prior to scanning. Uptake was detected in 42 cases with active disease (53%); no uptake was noted in 28 cases (36%) without active disease, and in 9 cases (11%) the scan gave a false‐positive or a false‐negative result. The conclusions of this study are (1) 67 Ga scanning is useful in establishing the extent of lesions as well as the presence of undetected disease, (2) 67 Ga scanning is especially useful for the evaluation of the effectiveness of therapy.